Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/30/2024 | $19.00 | Buy | H.C. Wainwright |
| 8/28/2024 | $15.00 | Buy | Jefferies |
| 1/3/2024 | $4.00 → $8.00 | Neutral → Buy | Mizuho |
| 10/26/2023 | $57.00 → $4.00 | Buy → Neutral | Mizuho |
| 10/13/2023 | $32.00 → $6.00 | Buy → Neutral | Goldman |
| 9/7/2022 | $46.00 | Buy | Needham |
| 3/17/2022 | $45.00 | Buy | Goldman |
| 3/2/2022 | $35.00 → $37.00 | Overweight | Morgan Stanley |
WESTLAKE VILLAGE, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 14,000 restricted stock units of Arcutis' common stock to two newly hired employees. These awards were approved by the Compensation Committee of Arcutis' Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of July 1, 2025, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4). The restricted
The American Academy of Dermatology (AAD) provided evidence-based recommendation for the use of ZORYVE® (roflumilast) cream 0.15% in adults with mild to moderate atopic dermatitis (AD)Recommendation reflects ZORYVE's proven efficacy, safety, and tolerability as a next-generation, steroid-free, topical phosphodiesterase-4 (PDE4) inhibitorAmong newly evaluated branded topical therapies, ZORYVE is the only treatment with a strong recommendation for adults with mild to moderate atopic dermatitis in AAD's focused guideline updateZORYVE is the first FDA-approved branded topical PDE4 inhibitor indicated for AD, plaque psoriasis, and seborrheic dermatitisAD impacts over 16 million adults in the Unit
Four-week Phase 2 study to evaluate investigational, once-daily ZORYVE .05% in infants as young as 3 months to less than 2 years with atopic dermatitisAtopic dermatitis impacts 9.6 million children in the United States; up to 60% of children with atopic dermatitis develop symptoms within their first year WESTLAKE VILLAGE, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that the first child has been enrolled in a Phase 2 open-label study, INTEGUMENT-INFANT, evaluating the safety and tolerability of investigational ZORYVE (ro
4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
8-K - Arcutis Biotherapeutics, Inc. (0001787306) (Filer)
SCHEDULE 13G/A - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)
SCHEDULE 13G/A - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)
4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
Submission status for ARCUTIS BIOTHERAPEUTICS INC's drug ZORYVE (ORIG-1) with active ingredient ROFLUMILAST has changed to 'Approval' on 12/15/2023. Application Category: NDA, Application Number: 217242, Application Classification: Type 3 - New Dosage Form
Submission status for ARCUTIS BIOTHERAPEUTICS INC's drug ZORYVE (ORIG-1) with active ingredient ROFLUMILAST has changed to 'Approval' on 12/15/2023. Application Category: NDA, Application Number: 217242, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination
Industry veteran with deep commercial experience in dermatology and immunologyAyisha Jeter appointed Senior Vice President, Marketing and Market Access WESTLAKE VILLAGE, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the appointment of Todd Edwards as Chief Commercial Officer (CCO), effective immediately. Mr. Edwards brings to Arcutis over 25 years of sales, market access, marketing, and general management experience from leading companies in dermatology and immunology, including Incyte, UCB, and AbbVie. "We are t
Senior Vice President and Chief Commercial Officer (CCO) Ken Lock Stepping DownAyisha Jeter Appointed Interim CCO WESTLAKE VILLAGE, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced a leadership change. Ken Lock, who has served as Senior Vice President and Chief Commercial Officer (CCO) since October 2019, is stepping down to attend to personal matters effective June 2, 2023. During this transition period, Arcutis' Vice President of Market Access, Ayisha Jeter, has been appointed interim CCO. Mr. Lock's contributions t
WESTLAKE VILLAGE, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the appointment of Mas Matsuda, Esq. as General Counsel and Corporate Secretary. Mr. Matsuda joins Arcutis from Halozyme Therapeutics Inc. and succeeds Keith Klein, Esq. who announced his retirement after a successful 30-year industry career. In this role, Mr. Matsuda will oversee all legal and compliance matters for the Company. "On behalf of our entire team, we'd like to thank Keith for his considerable contributions to our efforts in establishing Arcutis as a le
SC 13G/A - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)
SC 13G/A - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)
SC 13G/A - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)
Q1 2025 net product revenue for ZORYVE® (roflumilast) was $63.8 million, a 196% increase compared to Q1 of 2024, and a 2% decrease compared to Q4 of 2024, due to typical first-quarter deductible resets and insurance changes, and excluding the non-recurring reduction in reserves for product return of $4.1 million reported in Q4 2024Continued demand growth for ZORYVE of 10%, solidifying its position as most prescribed branded non-steroidal topical treatment across three major inflammatory skin conditionsAll three largest national Pharmacy Benefit Managers (PBMs) covering entire ZORYVE portfolio and Medicaid coverage continues to expandOn April 3, 2025, the patent litigation against Padagis was
WESTLAKE VILLAGE, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report first quarter 2025 financial results and provide a business update on Tuesday, May 6, 2025 after the U.S. financial markets close. The Company will also host a conference call and webcast the same day at 4:30 p.m. ET. A live webcast of the call and the presentation materials will be available on the "Events" section of The Company's website. An archived replay of the webcast will be available on the Arcutis investor website following th
WESTLAKE VILLAGE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Q4 2024 net product revenue for ZORYVE® (roflumilast) was $69.4 million, a 413% increase compared to Q4 of 2023 and a 55% increase compared to Q3 of 2024; driven by strong portfolio demand growth and including a non-recurring adjustment of $4.1 million due to a reduction in reserves for product returnsFull Year 2024 net product revenue for ZORYVE was $166.5 million, an increase of 471% over the prior year, setting the stage for sustained growth and strong financial position in 2025ZORYVE is now the most prescribed branded non-steroidal topical treatment across three major inflammatory skin conditions combined in the United StatesS
H.C. Wainwright initiated coverage of Arcutis Biotherapeutics with a rating of Buy and set a new price target of $19.00
Jefferies initiated coverage of Arcutis Biotherapeutics with a rating of Buy and set a new price target of $15.00
Mizuho upgraded Arcutis Biotherapeutics from Neutral to Buy and set a new price target of $8.00 from $4.00 previously